# A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

> **NCT05732805** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Biocad** · enrollment: 270 (estimated)

## Conditions studied

- Melanoma
- Melanoma (Skin)
- Melanoma Stage III
- Melanoma Stage IV
- Melanoma Unresectable
- Melanoma Metastatic
- Melanoma Advanced

## Interventions

- **BIOLOGICAL:** BCD-217
- **BIOLOGICAL:** BCD-100
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05732805
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-02
- **Primary completion:** 2024-06-20
- **Final completion:** 2025-07
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732805, "A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05732805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*